Artivion Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $123.8 million, up 9% year over year
- ➤Q3 net loss $(7.9) million versus $6.5 million net income
- ➤2026 revenue outlook narrowed to $484–$492 million, up 8%–10%
- ➤2026 adjusted EBITDA outlook narrowed to $93–$98 million
- ➤Adjusted EBITDA fell 8% to $22.5 million in Q3
Expert Statements
Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion
“In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio. Revenue growth was led by On-X, which grew 13% on a constant currency basis compared to the third quarter of 2025. Stent grafts revenue grew 12% for the second consecutive quarter, despite a tougher AMDS prior year comparison.”
Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion
“The number of U.S. AMDS implants increased from the second quarter, which we believe reflects the impact of our recent PMA approval and our efforts to drive adoption of this new technology. Preparations for the U.S. commercial launch of NEXUS in January 2027 are progressing well, and we look forward to our first surgeon training event in December. We also exited the quarter in a strong supply position for On-X following our investments in our Austin manufacturing facility, and ARTIZEN, our clinical trial for ARCEVO LSA, continues to enroll on schedule.”
Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion
“Overall, we are encouraged by our third quarter performance and the progress we have made so far in 2026. With the recent PMAs of AMDS and NEXUS in the U.S., and ARCEVO LSA on track with enrollment in the ARTIZEN IDE trial, we believe we are on track to being the only company with a comprehensive aortic arch portfolio, which represents an approximately $330 million annual U.S. market opportunity.”
Artivion Reports Third Quarter 2026 Financial Results PR Newswire
* Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and 9% on a non-GAAP constant currency basis * Net loss for the third quarter of 2026 was $(7.9) million, or $(0.16) per fully diluted share, and non-GAAP net income was $3.8 million, or $0.08 per fully diluted share * Adjusted EBITDA declined 8% to $22.5 million in the third quarter of 2026 compared to $24.6 million in the third quarter of 2025 ATLANTA, Nov. 5, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.